AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14600073
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hydrocortisone infusion (II) and GH (III) (IV)
Trial: 11726420
Drug: Inhaled milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled milrinone (0.25, 0.5, and 1 mg/mL)
Trial: 11726420
Drug: iPGI(2) (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iPGI(2) (10 microg/mL)
Trial: 11726420
Drug: iPGI(2) (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iPGI(2) (10 microg/mL) + inhaled milrinone (1 mg/mL)
Trial: 9221483
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg b.i.d. and amoxicillin 1 g b.i.d. for 14 days followed by lansoprazole 30 mg q.d. for 14 days
Trial: 9221483
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg b.i.d. and amoxicillin 1 g b.i.d. for 14 days followed by omeprazole 20 mg q.d. for 14 days
Trial: 9221483
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg b.i.d. and amoxicillin 1 g b.i.d. for 14 days
Trial: 9221483
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d., bismuth-subcitrate 120 mg q.i.d., and lansoprazole 30 mg for 10 days)
Trial: 3662908
Drug: Topical epinephrine
RxNorm normalized name: epinephrine Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical epinephrine (1.25%) applied twice daily
Trial: 3662908
Drug: Topical indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical indomethacin (0.5%) applied three times daily
Trial: 3662908
Drug: Topical indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical indomethacin placebo applied three times daily
Trial: 3662908
Drug: Topical epinephrine
RxNorm normalized name: epinephrine Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical epinephrine (1.25%)
Trial: 27562221
Drug: Access therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Access therapy with PRF + 1% ALN
Trial: 27562221
Drug: Access therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Access therapy with PRF
Trial: 27562221
Drug: Access therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Access therapy alone
Trial: 25635577
Drug: Ocriplasmin (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocriplasmin (125 µg)
Trial: 18356546
Drug: tPA +
RxNorm normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tPA + TCD + 2.8 mL microS (Target)
Trial: 17201276
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy of cardiac insufficiency
Trial: 15268733
Drug: Sirolimus (4-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (4-8 ng/mL) plus Tacrolimus (8-12 ng/mL for 3 months, then 5-10 ng/mL)
Trial: 15268733
Drug: Sirolimus (8-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (8-16 ng/mL) plus Tacrolimus (3-8 ng/mL, with tacrolimus elimination from month 3)
Trial: 15268733
Drug: Sirolimus (8-16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (8-16 ng/mL) plus Tacrolimus (3-8 ng/mL, with tacrolimus elimination from month 3) after protocol amendment
Trial: 11194595
Drug: Short bursts
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short bursts (5 s) without treatment (group A)
Trial: 11194595
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of propafenone 600 mg with short bursts (group B)
Trial: 11194595
Drug: Prolonged bursts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged bursts (30 s) without treatment (group C)
Trial: 11194595
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of propafenone 600 mg with prolonged bursts (group D)
Trial: 3933287
Drug: HCFU (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCFU (600 mg/day)
Trial: 3933287
Drug: Tegafur (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegafur (800 mg/day)
Trial: 3933287
Drug: HCFU (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCFU (in patients taking drugs for more than 90 days)
Trial: 3933287
Drug: Tegafur (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegafur (in patients taking drugs for more than 90 days)
Trial: 31867637
Drug: Very Low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very Low Nicotine Cigarettes (VLNC; 0.4 mg nicotine/g tobacco)
Trial: 22471127
Drug: Acupoint sticking
RxNorm normalized name: Zit Stick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint sticking therapy with Xiongbai Qianlie powder
Trial: 20702745
Drug: Twice-weekly MMN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly MMN
Trial: 20702745
Drug: Once-weekly MMN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly MMN
Trial: 20702745
Drug: Twice-weekly IFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly IFA
Trial: 11534421
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UH) administered in continuous intravenous infusion
Trial: 11534421
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) - sodic dalteparine with dicumarinic afterwards
Trial: 9342997
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of medications
Trial: 27592828
Drug: β‐CRX-rich orange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β‐CRX-rich orange juice (125 mL, once a day, after breakfast)
Trial: 27592828
Drug: Placebo (β‐CRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (β‐CRX removed from orange juice, 125 mL, once a day, after breakfast)
Trial: 24118703
Drug: Response-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Response-guided therapy (RGT) with boceprevir plus peginterferon alfa-2b and ribavirin (BOC/PR)
Trial: 24118703
Drug: Response-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Response-guided therapy (RGT)
Trial: 22085697
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg pregabalin + 10 mg oxycodone
Trial: 18275008
Drug: Risedronate 35
RxNorm normalized name: risedronate 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 35 mg once weekly (n=21)
Trial: 18275008
Drug: Teriparatide 20
RxNorm normalized name: TERIPARATIDE 200UNT/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide 20 microg once daily (n=23)
Trial: 12064847
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) - 6 sessions
Trial: 17050503
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg lisinopril
Trial: 6458919
Drug: Theophylline capsules
RxNorm normalized name: Theophylline Capsules
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline capsules
Trial: 6436931
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 500 mg intravenously
Trial: 6436931
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA), indomethacin, noramidopyrine intravenously, and acetaminophen orally during a bronchospastic attack
Trial: 25041619
Drug: Allogeneic living
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic living cell bioformulation with compression therapy
Trial: 22943926
Drug: Single-dose delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose delivery system (SDS)
Trial: 22943926
Drug: Multi-dose delivery
RxNorm normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-dose delivery system (MDS)
Trial: 22943926
Drug: Single-dose delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose delivery system (SDS) and Multi-dose delivery system (MDS)
Trial: 20934572
Drug: Fenofibric acid
RxNorm normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibric acid 135 mg + Atorvastatin 40 mg + Ezetimibe 10 mg (FA + Atorva/Eze)
Trial: 20934572
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg + Ezetimibe 10 mg (Atorva/Eze)
Trial: 17002609
Drug: Clinical response
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical response during the first days of treatment
Trial: 3900796
Drug: Milenperone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milenperone (2 X 10 mg daily for 6 weeks)
Trial: 8772689
Drug: Plasma norepinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma norepinephrine (PNE) levels above the median of 393 pg/mL
Trial: 6419264
Drug: 3-cyano-imipramine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-cyano-imipramine (1 mg rising to 3 mg daily for 7 days)
Trial: 29107059
Drug: PHARMA (optimized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHARMA (optimized pharmacological treatment)
Trial: 23283758
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) at a dosage of .3 mg/kg
Trial: 12806341
Drug: 35% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35% hydrogen peroxide bleaching agent, bonded immediately (Group B)
Trial: 12806341
Drug: 35% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35% hydrogen peroxide bleaching agent, stored in artificial saliva for 30 days before bonding (Group C)
Trial: 10827367
Drug: TEE‐guided subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEE‐guided subcutaneous enoxaparin bridge therapy
Trial: 10827367
Drug: TEE‐guided intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEE‐guided intravenous unfractionated heparin bridge therapy
Trial: 1513578
Drug: Heparin surface
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin surface modified IOL
Trial: 26531095
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 supplementation (1800 mg per day)
Trial: 25294055
Drug: SaiLuoTong 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SaiLuoTong 360 mg per day for 52 weeks
Trial: 25294055
Drug: SaiLuoTong 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SaiLuoTong 240 mg per day for 52 weeks
Trial: 25294055
Drug: SaiLuoTong 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SaiLuoTong 360 mg per day during the extension phase
Trial: 25294055
Drug: SaiLuoTong 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SaiLuoTong 240 mg per day during the extension phase
Trial: 19653976
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel (7.5 g daily for 12 weeks)
Trial: 19653976
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (7.5 g daily for 12 weeks)
Trial: 19653976
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone gel (7.5 g daily during open-label phase)
Trial: 19653976
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (7.5 g daily during open-label phase)
Trial: 17761977
Drug: CI-1033 50
RxNorm normalized name: CI 77266
DrugBank: Carbon black (DB11980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-1033 50 mg daily for 21 consecutive days
Trial: 17761977
Drug: CI-1033 150
RxNorm normalized name: CI 77266
DrugBank: Carbon black (DB11980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-1033 150 mg daily for 21 consecutive days
Trial: 17761977
Drug: CI-1033 450
RxNorm normalized name: CI 77266
DrugBank: Carbon black (DB11980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-1033 450 mg daily for 14 consecutive days followed by 7 days of no treatment
Trial: 15549466
Drug: 1% ropivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% ropivacaine, 12 ml
Trial: 15549466
Drug: 2% mepivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% mepivacaine, 18 ml
Trial: 8836468
Drug: Yohimbine (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (in combination with other drugs)
Trial: 8836468
Drug: Other medications
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other medications containing yohimbine
Trial: 8836468
Drug: Yohimbine plus
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine plus other drugs (uncontrolled trials)
Trial: 2271802
Drug: Group behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group behavioral medicine interventions (two types)
Trial: 492047
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml Trental (= 200 mg pentoxifylline)
Trial: 492047
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline solution (= placebo)
Trial: 27054321
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea supplementation (0.56 g/d epigallocatechin-gallate + 0.28 ∼ 0.45 g/d caffeine)
Trial: 1555981
Drug: Pre- or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre- or postoperative radiation therapy (45 Gy/5 weeks)
Trial: 29068050
Drug: Nose blowing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nose blowing at least twice daily for the first 7 postoperative days
Trial: 26980614
Drug: iTBS administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iTBS administered over ipsilesional primary motor cortex (M1-stimulation group)
Trial: 25325205
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day bupropion
Trial: 22301476
Drug: CCIV (cell-culture-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCIV (cell-culture-derived influenza vaccine)
Trial: 22301476
Drug: TIV (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIV (conventional egg-derived trivalent influenza vaccine)
Trial: 20406241
Drug: Aliskiren 150
RxNorm normalized name: aliskiren 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 150 mg (up-titrated to 300 mg)
Trial: 20406241
Drug: Ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 5 mg (up-titrated to 10 mg)
Trial: 17623606
Drug: Intra-articular analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular analgesic mixture (adrenaline, morphine, bupivacaine) administered during ACL reconstruction (groups 3 and 4)
Trial: 17623606
Drug: Intra-articular analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular analgesic mixture (adrenaline, morphine, bupivacaine)
Trial: 17623606
Drug: No intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intra-articular analgesic (groups 1, 2, and 5)
Trial: 12392805
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly cognitive behavioral therapy sessions
Trial: 12392805
Drug: Once weekly
RxNorm normalized name: Actonel 35 4-Week Once Weekly Dosepack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly cognitive behavioral therapy sessions
Trial: 12392805
Drug: Biweekly cognitive
RxNorm normalized name: Biweekly Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biweekly cognitive behavioral therapy sessions
Trial: 10580197
Drug: Canarypox virus
RxNorm normalized name: Canarypox virus Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canarypox virus vaccine (vCP300)
Trial: 10580197
Drug: Control injections
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control injections
Trial: 2206824
Drug: Ciba-Geigy carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciba-Geigy carbamazepine preparation
Trial: 2206824
Drug: Ethical Generics
RxNorm normalized name: Genesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethical Generics carbamazepine preparation
Trial: 29781243
Drug: Probiotic supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplements containing Bifidobacterium and Lactobacillus
Trial: 28544702
Drug: Changes in
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes in high-fat dairy and cream intake
Trial: 21130513
Drug: DPP-IV inhibitor
RxNorm normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPP-IV inhibitor PF-734200 (multiple doses for 28 days)
Trial: 19608530
Drug: Valacyclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 500 mg once daily and Aspirin 350 mg twice daily
Trial: 17553909
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) plus non-steroidal anti-inflammatory drugs (NSAIDs)
Trial: 8165192
Drug: Sandimmune Neoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandimmune Neoral (microemulsion formulation)
Trial: 8165192
Drug: Sandimmune (commercial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sandimmune (commercial formulation)
Trial: 31297890
Drug: Breastfed infants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breastfed infants given formula supplements
Trial: 25299350
Drug: Extended-release tramadol
RxNorm normalized name: tramadol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release tramadol HCl 75 mg/acetaminophen 650 mg (TA-ER)
Trial: 25299350
Drug: Immediate-release tramadol
RxNorm normalized name: tramadol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release tramadol HCl 37.5 mg/acetaminophen 325 mg (TA-IR)
Trial: 15979735
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg i.v. dexamethasone preoperatively
Trial: 8727868
Drug: Felodipine (Plendil)
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine (Plendil) 10 mg
Trial: 28418835
Drug: DT2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DT2 treatment
Trial: 28418835
Drug: CMP4 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CMP4 treatment
Trial: 25377788
Drug: Percentage dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percentage dose protocol (group 1)
Trial: 25377788
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose protocol (group 2)
Trial: 20051190
Drug: Elapsed time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elapsed time to first bowel movement from initiation of bowel preparation
Trial: 20051190
Drug: Adequate bowel
RxNorm normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate bowel preparation
Trial: 11383595
Drug: Infliximab (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (5, 10, or 20 mg/kg body weight)
Trial: 9923056
Drug: Intranasal levocabastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal levocabastine
Trial: 4456575
Drug: Small doses
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small doses of heparin
Trial: 28202475
Drug: Carbohydrate (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (50 g) added to standard white-bread challenge
Trial: 28202475
Drug: Protein (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein (50 g) added to standard white-bread challenge
Trial: 28202475
Drug: Fat (11.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat (11.1 g) added to standard white-bread challenge